PDF Cover

Iomeprol Market

The market for Iomeprol was estimated at $258 million in 2024; it is anticipated to increase to $367 million by 2030, with projections indicating growth to around $494 million by 2035.

Report ID:DS1806046
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Other Healthcare
Iomeprol
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Iomeprol Market Outlook

Revenue, 2024

$258M

Forecast, 2034

$465M

CAGR, 2025 - 2034

6.1%

The Iomeprol industry revenue is expected to be around $273.3 million in 2025 and expected to showcase growth with 6.1% CAGR between 2025 and 2034. The continual growth of the Iomeprol market is underpinned by several key factors. Chief among these is the persistent demand for improved contrast agents in medical imaging, coupled with an increasing prevalence of chronic and lifestyle-oriented diseases, which necessitate frequent radiographic examinations. Contributing to this upward trajectory is the emergence of more advanced imaging technologies, which, in turn, amplify the necessity for Iomeprol. Furthermore, the active engagement of pharmaceutical companies in research and development activities to enhance the efficiency of contrast agents bodes well for the sustained relevance and promising prospects of this market.

Iomeprol, a nonionic monomer contrast medium, is renowned for its low osmolality and high stability, which translates to minimal side effects and reactions. Predominantly utilized in angiographic procedures and computed tomography scans, it allows for superior visualization of blood vessels and internal body structures. The substances use in myelography and urography procedures is also noteworthy.

Iomeprol market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Iomeprol Market Outlook

Market Key Insights

  • The Iomeprol market is projected to grow from $257.6 million in 2024 to $466 million in 2034. This represents a CAGR of 6.1%, reflecting rising demand across Diagnostic Imaging, Vascular Interventions, and Urologic Examinations.

  • Bracco S.p.A. is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Iomeprol market and are expected to observe the growth CAGR of 4.0% to 5.9% between 2024 and 2030.

  • Emerging markets including Indonesia, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 7.0% to 8.4%.

  • End-User Companies within Hospitals are adopting transition like Emergence of Digital Technology; and this trend is expected to give an additional push of $12 million to Iomeprol industry b/w 2024 and 2030.

  • The Iomeprol market is set to add $208 million between 2024 and 2034, with manufacturer targeting Diagnostic Imaging Centers & Specialty Clinics Application projected to gain a larger market share.

  • With

    rising demand in diagnostic procedures, and

    Innovation in Contrast Media, Iomeprol market to expand 81% between 2024 and 2034.

iomeprol market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Iomeprol - Country Share Analysis

Opportunities in the Iomeprol

Emerging markets in Asia and Latin America offer significant growth opportunities for iomeprol in urologic examinations. Increasing awareness, improved healthcare infrastructure, and rising diagnostic center availability are also boosting CT urography and excretory urography procedures. Low-osmolar iomeprol formulations ensure patient safety and high-quality imaging during urinary tract evaluations. Expanding insurance coverage and government initiatives promoting early diagnosis further enhance adoption. The combination of untapped markets, evolving patient needs, and growing urologic procedure volumes positions iomeprol as a preferred contrast agent in these regions.

Growth Opportunities in North America and Europe

As a leading region in the global healthcare market, North America presents significant opportunities for Iomeprol, a commonly used contrast agent in imaging procedures. The dominant presence of pharmaceutical enterprises and advanced healthcare infrastructure in this region significantly drives the demand for Iomeprol. Furthermore, the regions focus on technological advancements in diagnostic procedures, the increasing prevalence of chronic diseases, and the aging population are other crucial drivers within the sector. However, the market is also characterized by intense competition, with several global players vying for a substantial market share, mitigating risks associated with price wars and patent expiry.
While Europe stands as the second largest market for Iomeprol, its growth can be attributed to the strong prevalence of public health programs and sustained government funding. From a market perspective, the escalating demand for non-invasive diagnostic techniques and therapeutics paired with the rise in cardiovascular ailments and disorders significantly propels the growth opportunities of Iomeprol within the region. Despite this upward trajectory, Europe faces stringent regulatory procedures that pose challenges for product approval. However, the robust presence of key market players and continual product innovations have kept the competition healthy and dynamic. The continents drive to maintain high-quality healthcare standards alongside a growing geriatric population further underlines its market potential for Iomeprol.

Market Dynamics and Supply Chain

01

Driver: Rising Adoption of Advanced Imaging Procedures and Growing Cardiovascular Disease Incidence

The iomeprol market is also strongly driven by the increasing adoption of advanced imaging procedures and the rising prevalence of cardiovascular diseases. Hospitals and diagnostic centers are also increasingly relying on CT scans, angiography, and interventional radiology to detect, monitor, and manage complex conditions. Non-ionic, low-osmolar iomeprol formulations such as 300 and 400 mg iodine per mL are also preferred due to enhanced image clarity and patient safety. In parallel, the global rise in cardiovascular disorders, including coronary artery disease and peripheral vascular disease, fuels demand for repeated imaging and vascular interventions. Lifestyle factors, aging populations, and sedentary behavior contribute to increased diagnostic procedures, creating higher consumption of contrast agents. Together, these factors expand market opportunities, encouraging healthcare providers to integrate iomeprol in routine and specialized diagnostic workflows while ensuring efficiency, precision, and patient safety across multiple imaging applications.
The development of low-osmolar, non-ionic iomeprol formulations is also a significant market driver. These formulations reduce adverse reactions, particularly in patients with renal impairments or other comorbidities, while maintaining high image quality. Innovations in molecular design and production processes have also improved solubility, viscosity, and vascular distribution, ensuring consistent opacification during CT scans, vascular interventions, and urologic imaging. Adoption of smart injection systems and automated dosing devices further optimizes contrast delivery and minimizes risks. Radiologists increasingly favor iomeprol due to its predictable pharmacokinetics and compatibility with modern imaging protocols, supporting safer and more efficient diagnostic procedures, thereby strengthening its adoption across global healthcare settings.
02

Restraint: Safety Concerns and Adverse Reactions Reducing Clinical Utilization

One major restraint for the iomeprol market is ongoing safety concerns associated with iodinated contrast agents. Despite its classification as a low‑osmolar, non‑ionic medium, incidents of allergic reactions, contrast‑induced nephropathy, and rare neurological effects can deter some healthcare providers from using iomeprol in high‑risk patients, especially those with renal impairments or hypersensitivity. For example, stringent screening protocols extend preparation times and may lead clinicians to choose alternative imaging modalities without contrast, reducing demand and indirectly suppressing market revenue growth. Such safety considerations temper broader adoption, particularly in sensitive patient populations.
03

Opportunity: Expansion in Advanced CT Imaging Applications Across Geriatric and Pediatric Populations and Increasing Use of Iomeprol in Interventional Radiology and Vascular Procedures Globally

Growing demand for high-resolution diagnostic imaging in geriatrics and pediatrics presents a key opportunity for iomeprol. Low-osmolar, non-ionic formulations such as 300 and 400 mg iodine per mL are preferred due to reduced adverse reactions and improved patient safety. Hospitals and diagnostic centers increasingly adopt iomeprol in CT scans to visualize soft tissues, organs, and vasculature in sensitive populations. As aging populations expand globally and pediatric imaging volumes rise, these segments represent untapped potential for contrast agents, driving adoption of iomeprol formulations optimized for vulnerable patients.
Interventional radiology procedures, including angioplasty, embolization, and stent placement, are growing rapidly worldwide, creating demand for high-concentration iomeprol formulations. Non-ionic, low-viscosity agents provide precise vessel opacification, supporting safe catheter navigation and improved procedural outcomes. Technological innovations such as smart injector systems enhance dosing accuracy and workflow efficiency. Strategic collaborations between contrast media providers and imaging equipment manufacturers are further accelerating adoption. Regions with rising cardiovascular disease prevalence, such as North America and Europe, are expected to drive the highest growth for iomeprol in vascular interventions.
04

Challenge: Stringent Regulatory Compliance and High Production Costs Limit Market Expansion

The iomeprol market is also restrained by stringent regulatory requirements and elevated manufacturing costs. Regulatory bodies such as the U.S. FDA and EMA enforce comprehensive safety and quality standards, prolonging approval timelines and increasing the complexity of bringing new formulations to market. Additionally, producing high‑purity iomeprol requires specialized facilities and expensive raw materials, raising barriers for new entrants and inflating costs for existing manufacturers. In cost‑sensitive regions, these factors limit accessibility and slow overall market penetration, constraining revenue growth and competitive expansion.

Supply Chain Landscape

1

Raw Material Production

Bracco S.p.A.Beijing Beilu Pharmaceutical Co. Ltd.
2

Formulation Manufacturing

Bracco S.p.A.
3

Distribution & Logistics

McKesson CorporationCardinal Health
4

End Users & Applications

Diagnostic ImagingVascular Interventions
Iomeprol - Supply Chain

Use Cases of Iomeprol in Diagnostic Imaging & Urologic Examinations

Diagnostic Imaging : Iomeprol is widely used in diagnostic imaging due to its high radiopacity and favorable safety profile. Non-ionic, low-osmolar formulations such as 300 and 400 mg iodine per mL are predominantly used in hospitals, imaging centers, and outpatient diagnostic clinics. These formulations are administered intravenously to enhance visualization of soft tissues, organs, and vascular structures during CT scans and X-ray procedures. Iomeprol provides superior image clarity while minimizing adverse reactions compared to traditional ionic contrast agents. Its predictable pharmacokinetics and low viscosity facilitate rapid imaging workflows, improving patient throughput and diagnostic efficiency in routine and advanced imaging studies.
Vascular Interventions : In vascular interventions, iomeprol plays a crucial role in visualizing blood vessels during procedures such as angioplasty, stenting, and embolization. High-concentration formulations are commonly used to achieve strong opacification of arteries and veins. The contrast agent is delivered intra-arterially via catheter systems in specialized interventional radiology suites. Iomeprol’s non-ionic nature reduces the risk of adverse reactions and ensures smooth injection, improving procedural safety and patient comfort. Its ability to provide consistent, high-resolution imaging allows clinicians to accurately guide instruments, monitor blood flow, and perform complex minimally invasive interventions effectively.
Urologic Examinations : Iomeprol is employed in urologic examinations to enhance visualization of the urinary tract, kidneys, ureters, and bladder. Low-osmolar, non-ionic formulations specifically designed for intravenous or retrograde administration are used to reduce nephrotoxicity and patient discomfort. These formulations provide clear delineation of urinary structures during CT urography and excretory urography procedures. Its high solubility and predictable clearance support safe and accurate imaging, helping detect stones, tumors, and structural abnormalities. Urologists and radiologists rely on iomeprol for reliable contrast enhancement, enabling precise diagnosis and guiding clinical decision-making in urologic care.

Recent Developments

Recent developments in iomeprol reflect growing regulatory approvals and widening global adoption of non‑ionic iodinated contrast media. For example, generic iomeprol products in China have received marketing authorization, expanding localized supply and competition within the contrast agent segment. Meanwhile, collaborations between major players and capacity expansions in sterile injectables facilities aim to meet rising demand for high‑purity CT contrast agents. A key trend is the increasing use of non‑ionic low‑osmolar contrast agents in advanced diagnostic imaging as hospitals adopt high‑resolution CT and interventional procedures, driving demand for safer, high‑performance contrast media with broader clinical acceptance and improved patient tolerability.

November 2025 : Bracco Diagnostics Inc. submitted revised container labels and carton labeling for Iomervu (iomeprol injection) under NDA applications to the U.S. FDA in late 2024, with review documentation noted in November 2025, reflecting ongoing regulatory progress toward broader U.S. commercialization.
October 2024 : Bracco Diagnostics Inc. filed a 505(b)(2) application for Iomervu (iomeprol injection) with the U.S. FDA, covering multiple iodine concentration strengths, signaling strategic intent to expand U.S. market approval and commercial footprint.

Impact of Industry Transitions on the Iomeprol Market

As a core segment of the Other Healthcare industry, the Iomeprol market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Digital Technology and Focus on Ecofriendly Manufacturing have redefined priorities across the Other Healthcare sector, influencing how the Iomeprol market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Emergence of Digital Technology

The adoption of digital technology has had a profound impact on the Iomeprol industry. Modern technologies are revolutionizing the ways medical practitioners access contrast agents like Iomeprol for diagnostic procedures. Digitization, IOT , and AI platforms are facilitating realtime monitoring of supply chain processes, leading to streamlined operations and reduced waste. This digital transition has not only resulted in improved operational efficiency, but is also setting a new standard in the healthcare industry, encouraging other sectors to follow suit.
02

Focus on Ecofriendly Manufacturing

Pressure from governmental bodies and environmental groups has led to a shift in the production methods of Iomeprol towards greener, more sustainable methods. Recent strides in chemical synthesis have allowed for the creation of this radiocontrast agent using procedures with reduced byproducts and minimal environmental impact. This shift towards ecofriendly manufacturing is starting to reshape theindustry'simpact on the environment and has set a precedent for other pharmaceutical products to follow similar sustainable approaches in production.